Lupin gets USFDA nod for generic oral contraceptive pill 

The company has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Drospirenone Tablets in 4 mg strength, said the drug maker.

Published: 04th November 2022 07:25 PM  |   Last Updated: 04th November 2022 07:25 PM   |  A+A A-

lupin

An employee of Lupin Limited works at a reception at their headquarters in Mumbai. (File Photo | Reuters)

By PTI

NEW DELHI: Drug maker Lupin on Friday said it has received approval from the US health regulator to market Drospirenone tablets, used to prevent pregnancy, in the American market.

The company has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Drospirenone Tablets in 4 mg strength, the Mumbai-based drug maker said in a statement.

The company's product is the generic equivalent of Exeltis USA Inc's Slynd tablets, it added.

As per IQVIA MAT September 2022 data, Drospirenone tablets had estimated annual sales of USD 141 million in the US market.

Now we are on Telegram too. Follow us for updates
TAGS
Lupin USFDA contraceptive pill pregnancy
India Matters

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.